Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corp reported third quarter 2025 revenue of $21.5 million, marking a 5% increase year-over-year, driven by the adoption of its Zephyr Valve for severe emphysema. The company maintained an impressive gross margin of 75% while narrowing its net loss to $14.0 million, reflecting improved operational efficiency. Furthermore, with international sales increasing by 15%, Pulmonx's focus on disciplined execution, along with promising initiatives surrounding AeriSeal and AI-driven tools, underlines the company’s potential for sustainable growth.

Bears say

Pulmonx Corp's Q3 revenue of approximately $21.5 million reflects a sequential decline from Q2's $23.9 million, indicating a slower growth trajectory and contributing to a downward revision of annual revenue guidance to $90 million–$92 million. Additionally, the company's top-line growth and gross margins, which were at 72% in Q2, have been negatively impacted by mix and conversion timing issues. The recent management transition, with Glen French returning as CEO and Derrick Sung appointed as COO/CFO, introduces additional execution risks that may further weigh on the company's financial performance.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.